EAACI Congress 2025
BackFT08 - Biological treatment in asthmatic diseases
Saturday 14 Jun, 13:15 PM -
14:45 PM Glasgow, United Kingdom
Dochart 1
Flash Talks
13:15
Hereditary α-Tryptasemia in Severe Allergic Asthma: Impaired Lung Function, Reduced Type 2 Biomarkers, and Suboptimal Omalizumab Response
13:22
Targeted Metabolomic Profiling as a Tool for Assessing Response to Biologicals: a case of Dupilumab in Severe Allergic Asthma
13:29
Asthma Severity and Patient-Reported Outcomes in Patients With Asthma and Allergic Rhinitis Initiating Dupilumab in RAPID
13:36
Treatment Patterns in Patients Who Initiated Dupilumab in a Real-World Clinical Setting: The RAPID Registry
13:43
Proteomic Modulation by Dupilumab in Severe Seasonal Asthma: Insights from a Short-Term Treatment Study in Ole e 7-Sensitized Patients
13:50
Dupilumab as a New Therapeutical Approach in Patients with Severe Seasonal Asthma Caused by Olive Pollen Sensitization
13:57
Decrease in Eosinophil-Derived-Neurotoxin upon mepolizumab is associated with asthma improvement
14:04
Mepolizumab Improves and Sustains Asthma Control and Lung Function in Patients with Severe Asthma, Independent of Baseline IgE and FeNO in the Real World: 2-Year Results from REALITI-A
14:11
Inhaled Corticosteroid Reduction Effects on Asthma Outcomes after Three Years of Benralizumab Treatment in Severe Asthma Patients
14:18
Inflammatory markers in asthmatic patients receiving anti-interleukin-5 therapy
14:25
Evaluation of the concordance of definitions of Asthma Remission according to international guidelines in a cohort of patients treated with monoclonal antibodies for severe asthma
14:32
Prediction score for difficult-to-treat allergic bronchopulmonary aspergillosis
